Alnylam Pharmaceuticals, Inc. (ALNY) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Alnylam Pharmaceuticals reported revenue of $3.71B, up 65.2% from $2.25B the year before. Net income was $313.7M (a 8.4% net margin), or $2.33 per diluted share. Gross margin was 81.8% and operating margin was 13.5%. Operating activities generated $524.1M of cash, leaving $465.4M of free cash flow. At fiscal year end, Alnylam Pharmaceuticals held $4.97B in total assets against $4.18B in total liabilities, including $1.66B of cash and equivalents.
Open the full interactive Alnylam Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Alnylam Pharmaceuticals Key Stats
| Share Price | $223.82 |
|---|---|
| Market Cap | $30.95B |
| P/E Ratio | 96.1 |
| Revenue YoY Growth | +65.2% |
| 52-Week Range | $205.48 – $491.22 |
| Shares Outstanding | 133.6 million (basic, 2026 Q2) |
Alnylam Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $492.9M | $844.3M | $1.04B | $1.83B | $2.25B | $3.71B |
| Cost of Goods Sold | $78.1M | $115.0M | $140.2M | $268.2M | $306.5M | $677.2M |
| Gross Profit | $414.8M | $729.3M | $897.2M | $1.56B | $1.94B | $3.04B |
| Operating Income | -$828.4M | -$708.7M | -$785.1M | -$282.2M | -$176.9M | $501.6M |
| Pre-Tax Income | -$855.6M | -$852.1M | -$1.13B | -$433.5M | -$377.4M | $323.2M |
| Income Tax | $2.7M | $680,000 | $4.2M | $6.7M | -$99.2M | $9.4M |
| Net Income | -$858.3M | -$852.8M | -$1.13B | -$440.2M | -$278.2M | $313.7M |
| Diluted EPS | -$7.46 | -$7.20 | -$9.30 | -$3.52 | -$2.18 | $2.33 |
Alnylam Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.25B | $1.10B | $1.17B | $1.29B |
| Net Income | $251.1M | $186.4M | $206.0M | $164.5M |
| Diluted EPS | $1.84 | $1.38 | $1.51 | $1.21 |
Alnylam Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $496.6M | $820.0M | $866.4M | $812.7M | $966.4M | $1.66B |
| Current Assets | $2.61B | $2.81B | $2.69B | $2.98B | $3.30B | $4.05B |
| Total Assets | $3.41B | $3.64B | $3.55B | $3.83B | $4.24B | $4.97B |
| Current Liabilities | $585.3M | $695.7M | $767.9M | $967.8M | $1.19B | $1.47B |
| Total Long-Term Debt | $191.3M | $675.7M | $1.02B | $1.02B | $1.02B | $1.01B |
| Total Liabilities | $2.39B | $3.06B | $3.70B | $4.05B | $4.17B | $4.18B |
| Shareholders' Equity | $1.02B | $588.2M | -$158.2M | -$220.6M | $67.1M | $789.2M |
Alnylam Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$615.0M | -$641.7M | -$541.3M | $104.2M | -$8.3M | $524.1M |
| Cash From Investing | -$435.5M | -$273.3M | $169.4M | -$336.4M | -$116.8M | $436.3M |
| Cash From Financing | $995.0M | $1.25B | $425.8M | $172.1M | $294.2M | -$305.2M |
| Free Cash Flow | -$685.3M | -$718.1M | -$613.3M | $41.9M | -$42.6M | $465.4M |
Figures from Alnylam Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Alnylam Pharmaceuticals financials page for every line item.
Alnylam Pharmaceuticals Company Profile
| Ticker | ALNY |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001178670 |
Frequently Asked Questions
What was Alnylam Pharmaceuticals' revenue in fiscal 2025?
Alnylam Pharmaceuticals (ALNY) reported revenue of $3.71B for fiscal 2025.
What is Alnylam Pharmaceuticals' annual revenue history?
Alnylam Pharmaceuticals' annual revenue by fiscal year: 2020: $492.9M; 2021: $844.3M; 2022: $1.04B; 2023: $1.83B; 2024: $2.25B; 2025: $3.71B.
What was Alnylam Pharmaceuticals' net income in fiscal 2025?
Alnylam Pharmaceuticals reported net income of $313.7M for fiscal 2025.
What was Alnylam Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Alnylam Pharmaceuticals' diluted EPS was $2.33 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Alnylam Pharmaceuticals generate in fiscal 2025?
Alnylam Pharmaceuticals generated $465.4M of free cash flow in fiscal 2025.
What was Alnylam Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Alnylam Pharmaceuticals reported revenue of $1.29B.
How much debt does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals reported $1.01B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Alnylam Pharmaceuticals are outstanding?
Alnylam Pharmaceuticals reported a weighted average of 133.6 million basic shares outstanding in 2026 Q2.
What is Alnylam Pharmaceuticals' market cap?
Based on its latest closing price, Alnylam Pharmaceuticals (ALNY) has a market capitalization of about $30.95B.
When does Alnylam Pharmaceuticals' fiscal year end?
Alnylam Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Alnylam Pharmaceuticals headquartered?
Alnylam Pharmaceuticals lists its business address in Cambridge, Massachusetts in its SEC filings.